Increasing investment in Suzhou BeiGene steadily accelerates global industrialization layout

On June 9th, BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) announced the official launch of the new Suzhou innovative drug industrialization base project

Ou Leiqiang, founder, chairman and CEO of BeiGene, said: "The construction of a new industrialization base in Suzhou is another major move by BeiGene to accelerate its global industrialization and build a stable supply system

Improve high-quality sustainable production capacity

The total construction area of ​​the new Suzhou innovative drug industrialization base exceeds 82,000 square meters, which will be 6.

The development of high-quality drugs requires systematic solutions to many technical details

The quality and safety of medicines are a key focus of production, with strict supervision and regulatory requirements

Accelerate innovative drugs to benefit more patients

Recently, the company independent research and development of new cancer drugs third paragraph Parkway Chak ^® formally NMPA conditional marketing approval, and in just three days to achieve a seamless transition from the industrial base Suzhou shipped and delivered in the hands of patients, successfully Sent to 30 provinces (autonomous regions and municipalities) across the country

Dr.

Stimulate the vitality of Suzhou biomedical innovation

In recent years, Suzhou City has positioned itself at a high point, made every effort to build biomedicine into the “No.

Shen Mi, Deputy Mayor of Suzhou Municipal People’s Government, said: “At present, Suzhou is actively seizing the opportunity of integrated development in the Yangtze River Delta, and is striving to build an internationally renowned and domestically competitive'China

Dr.